You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (360Dx) – Leerink today upgraded its rating for shares of T2 Biosystems to Outperfrom from Market Perform and raised the target price to $12 from $5, following the US Food and Drug Administration's clearance of the firm's T2Bacteria Panel.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.